文献速递血管炎

测量巨细胞动脉炎的治疗结局与疾病活动度变化:为制定EULAR-ACR应答标准提供信息的系统文献综述

Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force.
PubMed 文献 · RMD Open · 2023-01-01

该系统文献综述检索了10593项研究,最终纳入116项(11项随机对照试验、104项纵向观察性研究、1项定性研究),旨在识别巨细胞动脉炎中用于衡量治疗应答和疾病活动度变化的标准与描述词。未发现统一的治疗应答定义;随机对照试验多采用复合终点,缓解和复发是主要治疗结局;活动性疾病多由临床与实验室指标组合定义。所识别的描述词将为未来制定EULAR-ACR巨细胞动脉炎应答标准提供信息。

要点

  • 未发现统一的巨细胞动脉炎治疗应答定义,各研究定义稀缺且异质。
  • 随机对照试验和纵向观察性研究主要以缓解和复发作为治疗结局。
  • 活动性疾病多由临床与实验室指标组合定义,复发还包含治疗相关成分。

核心结论

  • 该系统文献综述表明,巨细胞动脉炎临床研究中使用的应答定义稀缺且异质。
  • 随机对照试验和纵向观察性研究主要使用缓解和复发作为治疗结局。
  • 所识别的描述词将为未来制定EULAR-ACR巨细胞动脉炎应答标准提供信息。

研究设计与样本

  • 系统文献综述,检索随机对照试验和纵向观察性研究。
  • 共检索到10593项研究,纳入116项(11项随机对照试验、104项纵向观察性研究、1项定性研究)。
  • 纳入标准包括随机对照试验、受试者超过20例的纵向观察性研究以及定性研究。
  • 提取活动性疾病、缓解、应答、改善、恶化和复发的标准与描述词。

主要发现

  • 未发现统一的治疗应答定义。
  • 大多数随机对照试验使用复合终点评估治疗结局。
  • 活动性疾病在所有随机对照试验和19%的纵向观察性研究中被描述,主要由临床与实验室指标组合定义。
  • 缓解在73%的随机对照试验和42%的纵向观察性研究中有报告,主要定义为临床与实验室指标组合。
  • 复发在所有随机对照试验和86%的纵向观察性研究中有报告,主要定义为临床、实验室和治疗指标组合。

关键数值与推荐

  • 活动性疾病:在所有随机对照试验和19%的纵向观察性研究中被描述,主要由临床与实验室指标组合定义。
  • 缓解:在73%的随机对照试验和42%的纵向观察性研究中被报告,主要定义为临床与实验室指标组合。
  • 复发:在所有随机对照试验和86%的纵向观察性研究中被报告,主要定义为临床、实验室和治疗指标组合。
  • 一项纵向观察性研究报告的应答定义与其他研究中缓解的定义相似。
  • 改善很少用作终点,且多为缓解的替代指标;无研究专门定义恶化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify criteria and descriptors used to measure response to treatment and change in disease activity in giant cell arteritis (GCA). METHODS: A systematic literature review (SLR) to retrieve randomised controlled trials (RCTs) and longitudinal observational studies (LOS). Criteria and descriptors of active disease, remission, response, improvement, worsening and relapse were extracted. RCTs, LOS with >20 subjects, and qualitative research studies were included. RESULTS: 10 593 studies were retrieved, of which 116 were included (11 RCTs, 104 LOS, 1 qualitative study). No unified definition of response to therapy was found. Most RCTs used composite endpoints to assess treatment outcomes. Active disease was described in all RCTs and 19% of LOS; and was largely defined by a combination of clinical and laboratory components. Remission was reported in 73% of RCTs and 42% of LOS; It was predominantly defined as the combination of clinical and laboratory components. One LOS reported response with a definition resembling the definition of remission from other studies. Improvement was rarely used as an endpoint and it was mostly a surrogate of remission. No study specifically defined worsening. Relapse was reported in all RCTs and 86% of LOS. It was predominantly defined as the combination of clinical, laboratory and treatment components. CONCLUSIONS: The results of this SLR demonstrate that definitions of response used in clinical studies of GCA are scant and heterogeneous. RCTs and LOS mainly used remission and relapse as treatment outcomes. The descriptors identified will inform the development of the future European Alliance of Associations for Rheumatology-American College of Rheumatology response criteria for GCA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sanchez-Alvarez C, Bond M, Soowamber M, et al. Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force. RMD Open. 2023. PMID: 37349123. doi:10.1136/rmdopen-2023-003233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。